Prognostic value of Sox2 expression in digestive tract cancers: A meta-analysis.
10.1007/s11596-016-1584-9
- Author:
Xiao-Ming DU
1
;
Liu-Hua WANG
1
;
Xiao-Wen CHEN
1
;
Yi-Xiao LI
1
;
Yu-Cong LI
1
;
Yu-Wen CAO
2
Author Information
1. Department of Pathology & Key Laboratory of Xinjiang Endemic and Ethnic Diseases, Shihezi University School of Medicine, Shihezi, 832000, China.
2. Department of Pathology & Key Laboratory of Xinjiang Endemic and Ethnic Diseases, Shihezi University School of Medicine, Shihezi, 832000, China. cywwb2013@126.com.
- Publication Type:Journal Article
- Keywords:
Sox2;
digestive tract cancer;
meta-analysis;
prognosis
- MeSH:
Antineoplastic Agents;
therapeutic use;
Biomarkers, Tumor;
genetics;
metabolism;
Colorectal Neoplasms;
diagnosis;
drug therapy;
mortality;
pathology;
Esophageal Neoplasms;
diagnosis;
drug therapy;
mortality;
pathology;
Gastrointestinal Tract;
metabolism;
pathology;
Gene Expression;
Humans;
Neoadjuvant Therapy;
methods;
Neoplasm Grading;
Neoplasms, Vascular Tissue;
diagnosis;
drug therapy;
mortality;
secondary;
Prognosis;
SOXB1 Transcription Factors;
genetics;
metabolism;
Stomach Neoplasms;
diagnosis;
drug therapy;
mortality;
pathology;
Survival Analysis
- From:
Journal of Huazhong University of Science and Technology (Medical Sciences)
2016;36(3):305-312
- CountryChina
- Language:English
-
Abstract:
The aim of the present study was to accurately evaluate the association of Sox2 expression with the survival of patients with digestive tract cancers. Relevant literatures were identified by comprehensively searching databases including the Pubmed, Embase, CBMdisc, and Wanfang (up to October 2014). A meta-analysis was performed to clarify the association between Sox2 expression and overall survival or clinicopathological parameters of patients with digestive tract cancers (esophageal, gastric, and colorectal cancers). The results showed a significant association between high Sox2 expression and poor overall survival in patients with digestive tract carcinomas (HR=1.55, 95% CI=1.04-2.31), especially for patients with esophageal cancer (HR=2.04, 95%CI=1.30-3.22), colorectal cancer (HR=1.40, 95% CI=1.04-1.89), and digestive tract adenocarcinoma (HR=1.80, 95% CI=1.12-2.89), for Europeans (HR=1.98, 95% CI=1.44-2.71) or patients who did not receive neoadjuvant treatment (HR=1.73, 95% CI=1.10-2.72). Furthermore, Sox2 over-expression was highly correlated with vascular invasion (OR=1.86, 95% CI=1.25-2.77) and poor differentiation (OR=1.88, 95% CI=1.14-3.08), especially in esophageal and colorectal cancers. In conclusion, Sox2 expression may serve as a novel prognostic factor for patients with digestive tract cancers. Over-expression of Sox2 that is correlated with vascular invasion and poor differentiation suggests poor outcomes of patients with digestive tract cancers.
